Custirsen fails another phase 3 trial and appears nonviable

RobertC

Veteran Member

Joined : May 2011

Posts : 1336

Posted 8/16/2016 12:38 PM (GMT 0)

custirsen has failed the second of three late-stage trials in prostate cancer. This time, in a study called Affinity, custirsen, when combined with the steroid prednisone and the chemotherapy cabazitaxel, didn’t help extend the lives of prostate cancer patients who had already failed a round of chemo. In 2014, custirsen failed a trial in newly diagnosed prostate cancer patients.

Cyclone-ISU

Veteran Member

Joined : Oct 2014

Posts : 3388

Posted 8/16/2016 6:15 PM (GMT 0)

We "patiently" await that next BREAKTHROUGH medication or treatment ... alas ... trial and error ... the next elusive breakthrough ...

The American rocker Tom Petty had a hit song entitled "The WAITING Is The Hardest Part" ...

Just a few years ago, there was the GLORIOUS arrival of XTANDI ... ZYTIGA ... XOFIGO ...

We all wait ... hoping for that NEXT STEP breakthrough which can help our fellow brothers in the battle ...

Waiting, watching, hopeful,
"Cyclone Fan" ~ Iowa State University

RobertC

Veteran Member

Joined : May 2011

Posts : 1336

Posted 8/16/2016 8:20 PM (GMT 0)

Walsh included Custirsen as promising in his book.

Prostvac , apalutamide / ARN-509 and ODM-201 are still in phase 3 and could be significant. Some of these will pan out.

Cyclone-ISU

Veteran Member

Joined : Oct 2014

Posts : 3388

Posted 8/16/2016 8:26 PM (GMT 0)

Hello RobertC,

I'm standing here on the sidelines ... ready to help roll out the RED CARPET when that day comes !

Bring on the next wave of breakthroughs, I say, to one and all !

Appreciate the update,
"Cyclone" ~ Iowa State University

✚ New Topic ✚ Reply